Specific Inhibition of Influenza Virus RNA Polymerase and Nucleoprotein Gene Expression by Liposomally Encapsulated Antisense Phosphorothioate Oligonucleotides in MDCK Cells
Free accessResearch articleFirst published online June, 1998
Specific Inhibition of Influenza Virus RNA Polymerase and Nucleoprotein Gene Expression by Liposomally Encapsulated Antisense Phosphorothioate Oligonucleotides in MDCK Cells
We have demonstrated that antisense phosphorothioate oligonucleotides (S-ODNs) inhibit influenza A virus replication in MDCK cells. Liposomally encapsulated and free antisense S-ODNs with four target sites (PB1, PB2, PA and NP genes) were tested for their abilities to inhibit virus-induced cytopathogenic effects in a MTT assay using MDCK cells. The liposomally encapsulated S-ODN complementary to the site around the PB2 AUG initiation codon showed highly inhibitory effects. In contrast, the inhibitory effect of the liposomally encapsulated S-ODN targeted to PB1 was considerably decreased in comparison with that directed to the PB2 target site. The liposomally encapsulated antisense S-ODNs exhibited higher inhibitory activities than the free oligonucleotides, and showed sequence-specific inhibition, whereas free antisense S-ODNs were observed to inhibit viral adsorption to MDCK cells. Liposomal preparations of oligonucleotides facilitated their release from endocytic vesicles, and thus cytoplasmic and nuclear localization was observed. The activities of the antisense S-ODNs were effectively enhanced by using the liposomal carrier. Interestingly, the liposomally encapsulated FITC-S-ODN-PB2–as accumulated in the nuclear region of MDCK cells. However, weak fluorescence was observed within the endosomes and the cytoplasm of MDCK cells treated with the free antisense S-ODNs. The cationic lipid particles may thus be a potentially useful delivery vehicle for oligonucleotide-based therapeutics and transgenes, appropriate for use in vitro or in vivo.
AgrawalSGoodchildJCiveiraMPThorntonAHSarinPS & ZamecnikPC (1988) Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA85:7079–7083.
2.
AgrawalSGoodchildJCiveiraMPSarinPS & ZamecnikPC (1989) Phosphoramidate, phosphorothioate, and methylphosphonate analogs of oligodeoxynucleotide: inhibitors of replication of human immunodeficiency virus. Nucleosides & Nucleotides8:819–823.
3.
AkhtarS & JulianoRL (1992) Liposome delivery of antisense oligonucleotides: adsorption and efflux characteristics of phosphorothioate oligodeoxynucleotides. Journal of Controlled Release22:47–56.
4.
BeatonAR & KrugRM (1986) Transcription antitermination during influenza virus template RNA synthesis requires the nucleocapsid protein and the absence of a 5′-capped end. Proceedings of the National Academy of Sciences, USA83:6282–6286.
5.
BennettCFChaingM-YChangHSchoemakerJE & MirabelliCK (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Molecular Pharmacology41:1023–1033.
6.
BraamJUlmanenI & KrugRM (1983) Molecular model of a eucaryotic transcription complex: functions and movements of influenza P proteins during capped RNA-primed transcription. Cell34:609–618.
7.
CaplenNJGaoXHayesPElaswarapuRFisherGKinradeEChakeraASchorrJHughersBDorinJRPorteousDJAltonFWGeddesDMCoutelleCWilliamsonRHuangL & GilchristC (1994) Gene therapy for cystic fibrosis in humans by liposome-mediated DNA transfer: the production of resources and the regulatory process. Gene Therapy1:139–147.
8.
EricksonRP & YzantJG (1992) Gene Regulation: Biology of Antisense RNA and DNA.London: Raven Press.
9.
FelgnerJHKumerRSridharCNWheelerKTsaiYJBorderRRamseyPMartinM & FelgnerPL (1994) Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. Journal of Biological Chemistry269:2550–2561.
10.
HattaTKimS-GNakashimaHYamamotoNSakamotoKYokoyamaS & TakakuH (1993) Mechanism of the inhibition of reverse transcription by unmodified and modified antisense oligonucleotides. FEBS Letters330:161–164.
11.
HattaTTakaiKNakadaSYokotaT & TakakuH (1997) Specific inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by liposomally endocapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells. Biochemical and Biophysical Research Communications232:545–549.
12.
HélèneC & ToulméJJ (1990) Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochemica et Biophysica Acta149:99–125.
13.
IyerRPEganWReganJB & BeaucageSL (1990) 3H-1,2-benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates. Journal of Organic Chemistry55:4693–4698.
14.
KapteinJS & NayakDP (1982) Complete nucleotide sequence of the polymerase 3 gene of human influenza virus A/WSN/33. Journal of Virology42:55–63.
15.
KbanovAVVinogradovSVOvcharenkoAVKrivonocAVMelik-NubarovNSKiselevVI & SeverinES (1990) A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substitutents effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells. FEBS Letters259:327–330.
16.
KimS-GSuzukiYNakashimaHYamamotoN & TakakuH (1991) Phosphorothioate analogues of oligodeoxyribonucleotides: synthesis and activity as inhibitors of replication of human immunodeficiency virus. Biochemical and Biophysical Research Communications179:1614–1619.
17.
KimS-GKanbaraKNakashimaHYamamotoNMurakamiK & TakakuH (1993) Anti-HIV activities and physicochemical properties of phosphorothioate analogues complementary to HIV sequences. Bioorganic and Medicinal Chemistry Letters3:1223–1228.
18.
KimS-GHattaTTsukaharaSNakashimaHYamamotoNShojiKTakaiK & TakakuH (1995) Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus. Bioorganic and Medicinal Chemistry3:49–54.
19.
KinchingtonDGalpinSJaroszewskiJWGhoshKSubasingheC & CohenJS (1992) A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1. Antiviral Research17:53–62.
20.
LeiterJMEAgrawalSPaleseP & ZamecnikPC (1990) Inhibition of influenza virus replication by phosphorothioate oligonucleotides. Proceedings of the National Academy of Sciences, USA87:3430–3434.
21.
LeonettiJPMachyPDegolsGLebleuB & LesermanL (1989) Antibody targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibited viral replication. Proceedings of the National Academy of Sciences, USA87:2448–2451.
22.
LeventisR & SilviusJR (1990) Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic ampliphiles. Biochemica et Biophysica Acta1023:124–132.
23.
LoganJLBebokZWalkerLCPengSFelgnerPSiegalG PFrizzellRADongJHowardMMatalonSLindsayJRDuvallM & SorcherEJ (1995) Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epitheliums. Gene Therapy2:38–49.
24.
LokeSLSteinCAZhangXHMoriKNakanishiMSubasingheCCohenJS & NeckersLM (1989) Characterization of oligonucleotide transport into living cells. Proceedings of the National Academy of Sciences, USA86:3474–3478.
25.
MajumdarCSteinCACohenJSBroderS & WilsonSH (1989) Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide. Biochemistry28:1340–1346.
26.
MatsukuraMShinozukaKZonGMitsuyaHReitMCohenJC & BroderS (1987) Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA84:7706–7710.
27.
MatsukuraMZonGShinozukaKRobert-GuroffMShimadaTSteinCAMitsuyaHWong-StaalFCohenJS & BroderS (1989) Regulation of viral expression of HIV in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev in chronically infected cells. Proceedings of the National Academy of Sciences, USA86:4244–4248.
28.
MauryGEl AlaouiAMorvanFMüllerBImbachJ-L & GoodyRS (1992) Template phosphorothioate oligonucleotide duplexes as inhibitors of HIV-1 reverse transcriptase. Biochemical and Biophysical Research Communications186:1249–1256.
29.
MilhaudPGMachyPColoteSLebleuB & LesermanL (1991) Free and liposome-encapsulated double-stranded RNAs as inducers of interferon, interleukin-6, and cellular toxicity. Journal of Interferon Research11:261–265.
30.
MillerPSMcParlandKBYayaramanN & Ts'oPOP (1981) Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry20:1874–1880.
31.
MillerPSAgrisCHAurelianLBlakeKRMurakamiAReddyMPSpitzSA & Ts'oPOP (1985) Control ribonuleic acid function by oligonucleotide methylphosphonates. Biochimie67:769–776.
32.
NakashimaHShojiYKimS-GShimadaJMizushimaYItoMYamamotoN & TakakuH (1994) Anti-human immunodeficiency virus type-1 activity of phosphorothioate analogs of oligodeoxynucleotides: penetration and localization in HIV-1–infected MOLT-4 cells. Nucleic Acids Research22:5004–5010.
33.
NewmanPCNwosuVUWilliamsDMCosstickRSeelaF & ConnollyBA (1990) Incorporation of a complete set of deoxyadenosine and thymidine analogs suitable for the study of protein nucleic acid interaction into oligodeoxynucleotides. Application to the EcoRV restriction endonuclease and modification methylase. Biochemistry29:9891–9901.
34.
PhilipRLiggittDPhilipMDazinP & DebsR (1993) In vivo gene delivery. Journal of Biological Chemistry268:16087–16090.
35.
PlotchSJBouloyMJUlmanenI & KrugRM (1981) Inhibition of influenza viral RNA transcription by capped RNA primers: a unique cap (m7GpppXm)-dependent virion endonuclease generates 5′-terminal RNA fragments that prime transcription. Cell23:847–858.
36.
PontiusB & BergP (1991) Rapid renaturation of complementary DNA strands mediated by cationic detergents: a role for high-probability binding domains in enhancing the kinetics of molecular assembly processes. Proceedings of the National Academy of Sciences, USA88:8237–8241.
37.
QuattroneADi PasqualeG & CapaccioliS (1995) Enhancing antisense oligonucleotide intracellular levels by means of cationic lipids as vectors. Biochemica1:25–29.
38.
RothenbergMJohnsonGLaughlinCGreenIGradockISarverN & ChenJS (1989) Oligodeoxynucleotides as antisense inhibitor of gene expression: therapeutic implications. Journal of the National Cancer Institute81:1538–1544.
SkorskiTNieborowska-SkorskaMNicolaidesNCSzczylikCIversenPIozzoRVZonG & CalabrettaB (1994) Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proceedings of the National Academy of Sciences, USA91:4504–4508.
41.
SmithCCAurelianLReddyMPMillerPS & Ts'oPOP (1986) Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. Proceedings of the National Academy of Sciences, USA83:2787–2791.
42.
StecWZonGEganW & StecB (1984) Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of oligodeoxyribonucleotides. Journal of the American Chemical Society106:6077–6079.
43.
SteinCA & CohenJS (1988) Oligonucleotides as inhibitors of gene expression. Cancer Research48:2659–2668.
44.
SteinCAMatsukuraMSubasingheCBroderS & CohenJS (1989) Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV. AIDS Research and Human Retroviruses5:639–646.
45.
SteinCANeckersLMNairBCMumbauerSHokeG & PalR (1991) Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4. Journal of Acquired Immune Deficiency Syndromes4:686–693.
46.
ThierryAR & DritschiloA (1992) Intracellular availability of unmodified phosphorothioate and liposomally encapsulated oligodeoxyribonucleotides for antisense activity. Nucleic Acids Research21:5691–5698.
47.
UlmanenIBroniB & KrugRM (1981a) Role of two of the influenza virus core P proteins in recognizing cap 1 structures (m7GpppXm) on mRNAs and in initiating viral RNA transcription. Proceedings of the National Academy of Sciences, USA78:7355–7359.
48.
UlmanenIBroniB & KrugRM (1981b) Influenza virus temperative-sensitive cap (m7GpppXm)-dependent endonuclease. Journal of Virology45:27–35.
49.
WalkerLIrwinWJ & AkhtarS (1995) Improved cellular delivery of antisense oligonucleotides using transferring receptor anti-body-oligonucleotide conjugates. Pharmacological Research12:1548–1553.
50.
WhitesellLRosolenA & NeckersLM (1991) In vitro modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide. Antisense Research and Development1:343–350.
51.
WickstromsELBaconTAGonzalezAFreemanDLLymanGH & WickstromE (1988) Human promyelocitic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide target against c-myc mRNA. Proceedings of the National Academy of Sciences, USA85:1028–1032.
52.
YakubovLADeevaEAZarytovaVFIvanovaEMRyteASYurchenkoLV & VlassovVV (1989) Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?Proceedings of the National Academy of Sciences, USA86:6454–6458.
53.
ZamecnikPC & StephensonML (1978) Inhibition of Rous sarcoma virus replication and transformation by a specific oligodeoxynucleotide. Proceedings of the National Academy of Sciences, USA75:280–286.
54.
ZamecnikPCGoodchildJTaguchiY & SarinPS (1986) Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic immunodeficiency oligonucleotides complementary to viral RNA. Proceedings of the National Academy of Sciences, USA83:4143–4146.
55.
ZelphatiOZonG & LesermanL (1993) Inhibition of HIV-1 in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. Antisense Research and Development3:323–338.
56.
ZerialAThuongNT & HélèneC (1987) Selective inhibition of the cytopathic effect of type A influenza virus by oligonucleotides covalently linked to an intercalating agent. Nucleic Acids Research5:9909–9919.
57.
ZhuNLiggittDLuiY & DebsR (1993) Systemic gene expression after intravenous DNA delivery into adult mice. Science261:209–211.
